BTIG lowered the firm’s price target on Establishment Labs (ESTA) to $62 from $65 and keeps a Buy rating on the shares after its Q3 results. The company’s U.S. Motiva launch is exceeding the bullish forecasts, though its LatAm market continues to face challenges, most notably in Brazil, where procedure volumes in certain regions declined as much as a 50% y/y, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs Reports Narrowed Losses and FDA Approval
- Establishment Labs Announces $50M Direct Offering
- Establishment Labs announces $50M registered direct offering
- Establishment Labs reports Q3 EPS (59c), consensus (61c)
- Mizuho medical devices analyst holds an analyst/industry conference call